MedTrace Logo

Extension Study for Patients Who Have Participated in a BMN 701 Study

NCT01435772 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-05-22

Study results available
· View outcomes & findings →

Summary

This is a Phase 2 open-label, multiple dose study of BMN 701 administered by IV infusion every 2 weeks (qow) to patients with late-onset Pompe disease.

Conditions

  • Pompe Disease

Interventions

BIOLOGICAL

BMN 701

GILT-tagged recombinant human GAA

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · BioMarin Pharmaceutical

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-15
Primary Completion
2016-09-09
Completion
2016-09-09

Countries

  • United States
  • Australia
  • France
  • Germany
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01435772 on ClinicalTrials.gov